Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. cut its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 83.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,700 shares of the company's stock after selling 111,300 shares during the period. Polar Asset Management Partners Inc.'s holdings in Guardant Health were worth $521,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of GH. Canton Hathaway LLC purchased a new stake in Guardant Health in the 2nd quarter worth approximately $59,000. Byrne Asset Management LLC purchased a new stake in Guardant Health in the 2nd quarter worth approximately $77,000. Fullcircle Wealth LLC purchased a new stake in Guardant Health in the 2nd quarter worth approximately $211,000. Bank of New York Mellon Corp lifted its stake in Guardant Health by 31.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,280,221 shares of the company's stock worth $36,973,000 after purchasing an additional 309,157 shares in the last quarter. Finally, Railway Pension Investments Ltd lifted its stake in Guardant Health by 63.8% in the 2nd quarter. Railway Pension Investments Ltd now owns 620,878 shares of the company's stock worth $17,931,000 after purchasing an additional 241,800 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the company's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company's stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 5.50% of the company's stock.

Guardant Health Price Performance

NASDAQ:GH traded down $0.24 during mid-day trading on Friday, hitting $36.87. 1,567,808 shares of the company's stock were exchanged, compared to its average volume of 2,065,089. The business has a fifty day moving average price of $26.60 and a 200 day moving average price of $27.73. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $38.53.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million during the quarter, compared to analysts' expectations of $170.49 million. During the same period in the previous year, the firm posted ($0.73) EPS. Guardant Health's revenue was up 33.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Leerink Partners lowered their price objective on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, October 17th. The Goldman Sachs Group raised their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Sanford C. Bernstein decreased their target price on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 30th. Piper Sandler lifted their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. Finally, UBS Group lifted their target price on shares of Guardant Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of "Moderate Buy" and an average price target of $40.60.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.